Research Paper Volume 14, Issue 16 pp 6689—6715
Prognostic alternative splicing events related splicing factors define the tumor microenvironment and pharmacogenomic landscape in lung adenocarcinoma
Figure 9. The SFscore predicts immunotherapeutic benefits. (A) The relative mRNA expression level of 42 immune checkpoints was compared between SFscore high versus low groups. (B–D) The relative distribution of T cell exclusion score, T cell dysfunction score and TIDE score were compared between SFscore high versus low groups in TCGA-LUAD cohort (P < 0.001). (E, F) The relative distribution of clonal neoantigens and sub-clonal neoantigens were compared between SFscore high versus low groups in TCGA-LUAD cohort (P < 0.05).